A worker conducts testing during the 2014 Ebola outbreak in Liberia. Credit: John Saindon/Centers for Disease Control and Prevention. CC BY 2.0.
Once a COVID-19 vaccine is approved for public use, officials around the world will face the monumental challenge of vaccinating billions of people, a logistical operation rife with thorny ethical questions. What if instead of orchestrating complicated and resource-intensive campaigns to vaccinate humans against emerging infectious diseases like COVID-19, we could instead stop the zoonotic diseases that sometimes leap from animals to people at their source? A small, but growing number of scientists think its possible to exploit the self-propagating properties of viruses and use them to spread immunity instead of disease. Can we beat viruses like SARS-CoV-2, the novel coronavirus, at their own game?
A virus that confers immunity throughout an animal population as it spreads in the wild could theoretically stop a zoonotic spillover event from happening, snuffing out the spark that could ignite the next pandemic. If the wild rats that host the deadly Lassa virus, for example, are vaccinated, the risks of a future outbreak among humans could be reduced. For at least 20 years, scientists have been experimenting with such self-spreading vaccines, work that continues to this day, and which has gained the attention of the US military.
For obvious reasons, public and scientific interest in vaccines is incredibly high, including in self-spreading vaccines, as they could be effective against zoonotic threats. The biologists Scott Nuismer and James Bull generated fresh media attention to self-spreading vaccines over the summer after publishing an article in the journal Nature Ecology & Evolution. But the subsequent reporting on the topic gives short shrift to the potentially significant downsides to releasing self-spreading vaccines into the environment.
Self-spreading vaccines could indeed entail serious risks, and the prospect of using them raises challenging questions.
Who decides, for instance, where and when a vaccine should be released? Once released, scientists will no longer be in control of the virus. It could mutate, as viruses naturally do. It may jump species. It will cross borders. There will be unexpected outcomes and unintended consequences. There always are.
While it may turn out to be technically feasible to fight emerging infectious diseases like COVID-19, AIDS, Ebola, and Zika with self-spreading viruses, and while the benefits may be significant, how does one weigh those benefits against what may be even greater risks?
How they work. Self-spreading vaccines are essentially genetically engineered viruses designed to move through populations in the same way as infectious diseases, but rather than causing disease, they confer protection. Built on the chassis of a benign virus, the vaccines have genetic material from a pathogen added to them that stimulates the creation of antibodies or white blood cells in infected hosts.
These vaccines could be particularly useful, some scientists say, for wildlife populations where direct vaccination is difficult due to issues like inaccessible habitats, poor infrastructure, high costs, or lack of resources. The idea, essentially, is to vaccinate a small proportion of a population through direct inoculation. These so-called founders will then passively spread the vaccine to other animals they encounter either by touch, sex, nursing, or breathing the same air. Gradually, these interactions could build up population-level immunity.
Self-spreading vaccines have some of their roots in efforts to reduce pest populations. Australian researchers described a virally spread immunocontraception, which hijacked the immune systems of infected animalsin this case a non-native mouse species in Australiaand prevented them from fertilizing offspring. The earliest self-spreading vaccine efforts targeted two highly lethal infectious diseases in the European rabbit population (myxoma virus and rabbit hemorrhagic disease virus). In 2001, Spanish researchers field-tested a vaccine in a wild rabbit population living on Isla del Aire, a small Spanish island just off Menorca. The vaccine spread to more than half the 300 rabbits on the island, and the trial was deemed a success.
In 2015, another team of researchers speculated on the development of a self-spreading vaccine for the Ebola virus that could be used on wild great apes like chimpanzees. Since then, scientists have come to see a wide array of animalsfrom wildlife such as bats, birds, and foxes to domesticated animals like dogs, pigs, and sheepas amenable to self-spreading vaccines.
So far, researchers have not developed experimental self-spreading vaccines for humans; there is no clear evidence that anybody is actively working on the technology. Nuismer and Bull argue, rather, that self-spreading vaccines present a revolutionary approach to control emerging infectious diseases before they even spill over from animals into the human population.
Zoonotic spillover is certainly a pressing problem; alongside SARS-CoV-2, HIV, Ebola virus, and the Zika virus, there are over a thousand other new viruses with zoonotic potential that have been detected in wild animals over the last decade. Prevention is better than a cure, Nuismer and Bull say in a New Scientist article. In their Nature Ecology & Evolution article, they claim they are poised to begin developing self-disseminating vaccines to target a wide range of human pathogens in animals.
Outside of an experiment, scientists would face massive technical and practical hurdles in identifying the most appropriate targets for intervention and ensuring immunity is maintained in the wildlife populations. Despite these substantial challenges, the potential security implications of self-spreading vaccines are even more serious.
The principal security concern is that of dual-use. In essence, this means that the same research that is used to develop self-spreading vaccines to prevent disease, could also be used to deliberately cause harm. You could, for instance, engineer triggers into a virus that cause immune system failures in infected people or animals, a bit like HIV does naturally. Or you could create triggers in a virus that cause a harmful autoimmune response, where the body starts attacking its own healthy cells and tissues.
The bioweapon question. While researchers may intend to make self-spreading vaccines, others could repurpose their science and develop biological weapons. Such a self-spreading weapon may prove uncontrollable and irreversible.
We dont have to dig very deep for a historical example of weaponized biology. As the apartheid-era South African biowarfare program shows, social, political, and scientific pressures can lead to the misuse of biological innovation.
Codenamed Project Coast, South Africas program was primarily focused on covert assassination weapons for use against individuals deemed a threat to the racist apartheid government. In addition to producing contraptions to inject poisons, Project Coast researchers developed techniques to lace sugar cubes with salmonella and cigarettes with Bacillus anthracis.
While there have been many biowarfare programs, including several that were far more elaborate and sophisticated, the South African program is particularly relevant in thinking through malicious uses of self-spreading vaccines. One of Project Coasts research projects aimed at developing a human anti-fertility vaccine.
The idea took hold during a time of widespread concern over worldwide population explosion. Schalk Van Rensburg, who oversaw fertility-related work at a Project Coast laboratory, told South Africas post-apartheid Truth and Reconciliation Commission, a forum for examining the sordid history of the era and laying the foundation for future peace and tolerance, that he thought the project was in line with the World Health Organizations attempts to curb rising global birth rates. He believed it could bring his lab international acclaim and funding. According to Van Rensburg, Wouter Basson, the director of the biowarfare program, said the military needed an anti-fertility vaccine so that female soldiers would not fall pregnant.
While some of the scientists involved in the project denied awareness of ulterior intentions or even that their fertility work was part of a military endeavor, Van Rensburg and Daniel Goosen, a lab director, told the Truth and Reconciliation Commission that the real intention behind the project was to selectively administer the contraceptive in secret to unwitting Black South African women.
In the end, the anti-fertility vaccine was not produced before Project Coast was officially closed down in 1995, 12 years after it was initiated. An early version was tested in baboons, but never in humans. South Africa isnt the only country to try and forcibly sterilize parts of its population. European countries, including Sweden and Switzerland, sterilized members of the Roma minority in the early half of the 20th century and some, like Slovakia, continued even beyond that. More recently, analysts have alleged that the Chinese government is sterilizing women in Xinjiang, a province with a large population of Uighur Muslims.
It doesnt take a massive leap of the imagination to see how the aims of South Africas anti-fertility vaccine project would have benefited from research into self-spreading vaccines, particularly if you combine it with current developments in pharmacogenomics, drug development, and personalized medicine. Taken together, these strands of research could help enable ultra-targeted biological warfare.
An expanding potential for abuse. The Biological Weapons Convention, the treaty that bans biological weapons, is nearly 50 years old. Negotiated and agreed to in the depths of the Cold War, the convention suffers from outdated modes of operation. There are also significant compliance assessment challenges. The convention certainly didnt stop South Africa from pursuing Project Coast in the early 1980s.
Self-spreading vaccine research is a small but growing field. At the moment, about 10 institutions are doing significant work in the area. These laboratories are primarily located in the United States, but some are in Europe and Australia, as well. As the field expands, so does the potential for abuse.
So far research has primarily been bankrolled by US government science and health funders like the National Science Foundation, the National Institutes of Health, and the Department of Health and Human Services. Private organizations like the Gates Foundation and academic institutions have also financed projects. Recently, the Defense Advanced Research Projects Agency (DARPA), sometimes thought of as the US militarys research and development wing, has gotten involved in the research. The University of California, Davis, for example, is working on a DARPA administered project called Prediction of Spillover Potential and Interventional En Masse Animal Vaccination to Prevent Emerging Pathogen Threats in Current and Future Zones of US Military Operation. According to a pamphlet, the project is creating the worlds first prototype of a self-disseminating vaccine designed to induce a high level of herd immunity (wildlife population level protection) against Lassa virus and Ebola.
Military investment in biological innovation for defensive or protective purposes is permissible under the Biological Weapons Convention, but it can still send the wrong signals. It could cause countries to doubt one anothers intentions and lead to tit-for-tat investment in potentially risky research, including in self-spreading vaccines. The result of research gone awry or biowarfare could be catastrophic for health and the environment.
At a time when the norm against chemical weapons is degrading, underscored most recently by the poisoning of Russian opposition leader Alexei Navalny with the nerve agent Novichoka crime for which many European officials blame Russiathe international community simply cant afford to have the same thing happen to the norm against the use of biological weapons. It would completely defy the spirit of the treaty if it seemed like states would even want to pursue high-risk dual use activities in biology.
Early, open, good-faith conversations about scientific aims and advances that cause particular dual-use concerns, as self-spreading vaccines do, are essential to exploring the broader stakes of certain technical trajectories. The University of California, Davis program is pursuing ways to incorporate an off switch to safely control the technology. And DARPA says any field experimentation related to the project would follow biosafety protocols. But these pledges wont suffice. Our ambition must be to make a collective decision about the technical pathways we are willing, or not willing, to take as a society.
The rest is here:
Scientists are working on vaccines that spread like a disease. What could possibly go wrong? - Bulletin of the Atomic Scientists
- Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer [Last Updated On: August 17th, 2024] [Originally Added On: May 3rd, 2010]
- A new mouse mutant of the Cdh23 gene with early-onset hearing loss facilitates evaluation of otoprotection drugs [Last Updated On: August 17th, 2024] [Originally Added On: August 2nd, 2010]
- Pharmacogenomics [Last Updated On: August 17th, 2024] [Originally Added On: October 10th, 2011]
- Drug Firms Want More Access to Genetic Specimens - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 14th, 2011]
- India joins genome club -Genomics in India - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 14th, 2011]
- Classic: Weinshilboum: Inherited Variations in Drug and Neurotransmitter Metabolism 1981 - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 14th, 2011]
- Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict... - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 24th, 2011]
- Antidepressant Use Increases Significantly - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 28th, 2011]
- Kelan G. Tantisira, MD, MPH - Video [Last Updated On: August 17th, 2024] [Originally Added On: October 31st, 2011]
- Human Security Thesis, personalized medicine, pharmacogenomics, Pharmacogenomics - Introduction - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 8th, 2011]
- Pamela Sklar: 2011 Allen Institute for Brain Science Symposium - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 8th, 2011]
- Pharmacy Doctor Oct 2011 A #1.wmv - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 13th, 2011]
- R. Stephanie Huang, PhD: The Role of Pharmacogenomics and Anticancer Drugs - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 19th, 2011]
- Individualized Molecular Testing for Personalized Medicine - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 21st, 2011]
- Where Science Meets Faith: Anticipating the Future - Video [Last Updated On: August 17th, 2024] [Originally Added On: November 28th, 2011]
- Pharmacogenomics of psychotropic drugs - Video [Last Updated On: August 17th, 2024] [Originally Added On: December 6th, 2011]
- 2008 IPIT Awards Seminar: Hans Hogerzeil - Video [Last Updated On: August 17th, 2024] [Originally Added On: December 7th, 2011]
- Asuragen CLIA Pharmacogenomic Services - Video [Last Updated On: August 17th, 2024] [Originally Added On: December 8th, 2011]
- Pilot Demonstration Projects Group 4: Pharmacogenomics - Alan Shuldiner - Video [Last Updated On: August 17th, 2024] [Originally Added On: December 16th, 2011]
- Pharmacogenomics - Howard McLeod - Video [Last Updated On: August 17th, 2024] [Originally Added On: December 17th, 2011]
- Clinical Implementation of Psychiatric Pharmacogenomics - David Mrazek - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 10th, 2012]
- PROMISE - Bionexus Partnership Launching montage - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 16th, 2012]
- Dr. William Figg: Handling Pharmacogenomic Information - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 19th, 2012]
- Using Payer Data to Analyze Impact of Pharmacogenomic Approaches - Robert Epstein - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 22nd, 2012]
- Dr. Russ Altman on Pharmacogenomics - Video [Last Updated On: August 17th, 2024] [Originally Added On: January 26th, 2012]
- AssureRx Health Secures $8M Financing with Silicon Valley Bank to Support Growth [Last Updated On: August 17th, 2024] [Originally Added On: January 31st, 2012]
- BSc Biomedical Sciences courses at Brunel University - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 1st, 2012]
- Companion Diagnostics Market to Explode as Personalized Medicine Market Catapults to $42 Billion by 2015 [Last Updated On: August 17th, 2024] [Originally Added On: February 3rd, 2012]
- Gaming Wins Big at National Science Foundation's Visualization Challenge [Last Updated On: August 17th, 2024] [Originally Added On: February 14th, 2012]
- SBCE to organise international meet on Molecular Medicine [Last Updated On: August 17th, 2024] [Originally Added On: February 15th, 2012]
- FDA Evaluating MolecularHealth's MASE for Analyzing Post-Market Drug Safety [Last Updated On: August 17th, 2024] [Originally Added On: February 15th, 2012]
- Genome BC Funds $9.8M Project to Identify Subgroups in Medulloblastoma for Personalized Treatment [Last Updated On: August 17th, 2024] [Originally Added On: February 15th, 2012]
- Future US Nucleic Acid Testing Market Outlook [Last Updated On: August 17th, 2024] [Originally Added On: February 16th, 2012]
- China Clears Its First Microarray Platform for in Vitro Diagnostics to Accelerate Personalized Medicine [Last Updated On: August 17th, 2024] [Originally Added On: February 16th, 2012]
- ACLA Says Cuts in Medicare Lab Payments Could Hurt Nascent Personalized Dx Segment [Last Updated On: August 17th, 2024] [Originally Added On: February 20th, 2012]
- OncTerm- Pharmacogenomics - Video [Last Updated On: August 17th, 2024] [Originally Added On: February 21st, 2012]
- A Negative Vote for Vivus Obesity Drug, Says 'FDA Panel Whisperer' [Last Updated On: August 17th, 2024] [Originally Added On: February 22nd, 2012]
- International meet on molecular medicine begins at SBCE [Last Updated On: August 17th, 2024] [Originally Added On: February 24th, 2012]
- Demonstrating Cost Effectiveness of Clinical NGS is Key to Payor Reimbursement, Hospital Uptake [Last Updated On: August 17th, 2024] [Originally Added On: February 24th, 2012]
- Darien High Schoolers fare well at science fair [Last Updated On: August 17th, 2024] [Originally Added On: February 27th, 2012]
- US Hematology & Flow Cytometry Market Future Discussed in New Report Published at MarketPublishers.com [Last Updated On: August 17th, 2024] [Originally Added On: February 29th, 2012]
- ACM Global Central Lab Launches Workshop Series to Share Expert Insights on Navigating Global Clinical Trials with a ... [Last Updated On: August 17th, 2024] [Originally Added On: February 29th, 2012]
- Fitch: Drug Makers Continue to Face Challenges at the Beginning of the Drug Channel [Last Updated On: August 17th, 2024] [Originally Added On: February 29th, 2012]
- Will PCORI's Patient-Centered Comparative Effectiveness Research Track with Personalized Rx? [Last Updated On: August 17th, 2024] [Originally Added On: March 3rd, 2012]
- Generex to Meet with FDA about AE37 HER2 Peptide Vaccine; Companion Dx Path Still Unclear [Last Updated On: August 17th, 2024] [Originally Added On: March 6th, 2012]
- Vermillion's OVA1 Test Assigned Category 1 CPT Code; Stock Jumps [Last Updated On: August 17th, 2024] [Originally Added On: March 7th, 2012]
- Transgenomic Reports Fiscal Year 2011 Financial Results [Last Updated On: August 17th, 2024] [Originally Added On: March 7th, 2012]
- Transgenomic's Q4 Revenues Increase 69 Percent [Last Updated On: August 17th, 2024] [Originally Added On: March 7th, 2012]
- Research and Markets: Molecular Diagnostics: Market Segmentation and Opportunities - Emphasis on NGS and Its Emerging ... [Last Updated On: August 17th, 2024] [Originally Added On: March 7th, 2012]
- AMA Approves Vermillion MAAA Category 1 Code for OVA1; Will it Improve Reimbursement? [Last Updated On: August 17th, 2024] [Originally Added On: March 7th, 2012]
- USPSTF Updating BRCA Testing Recommendations for Asymptomatic Women; Accepting Public Input [Last Updated On: August 17th, 2024] [Originally Added On: March 8th, 2012]
- Global Biochips Market to Reach US$4.6 Billion by 2017, According to New Report by Global Industry Analysts, Inc. [Last Updated On: August 17th, 2024] [Originally Added On: March 10th, 2012]
- WSU venturing into pharmacogenomics - Tue, 13 Mar 2012 PST [Last Updated On: August 17th, 2024] [Originally Added On: March 13th, 2012]
- Research and Markets: Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice (6th ... [Last Updated On: August 17th, 2024] [Originally Added On: March 14th, 2012]
- With MDx Usage and Costs on the Rise, UnitedHealthCare Urges Reimbursement Reform [Last Updated On: August 17th, 2024] [Originally Added On: March 14th, 2012]
- Bioinformatics Market Outlook to 2015 [Last Updated On: August 17th, 2024] [Originally Added On: March 15th, 2012]
- WSU recruits geneticists in new research venture [Last Updated On: August 17th, 2024] [Originally Added On: March 15th, 2012]
- Pharmacogenomics - Video [Last Updated On: August 17th, 2024] [Originally Added On: March 15th, 2012]
- Free Book Download - Psychiatric Pharmacogenomics - Video [Last Updated On: August 17th, 2024] [Originally Added On: March 16th, 2012]
- PanGenX Takes Semantic-based Approach to Data Integration, Analytics for Personalized Medicine [Last Updated On: August 17th, 2024] [Originally Added On: March 17th, 2012]
- Research and Markets: Bioinformatics Market Outlook to 2015 [Last Updated On: August 17th, 2024] [Originally Added On: March 21st, 2012]
- Quest Launches MDx that May Predict Kidney Transplant Rejection Earlier than Current Methods [Last Updated On: August 17th, 2024] [Originally Added On: March 21st, 2012]
- EMERGE Network Launches Publicly Available Database of Phenotype Identification Algorithms [Last Updated On: August 17th, 2024] [Originally Added On: March 23rd, 2012]
- Prospective Outcomes Trial Shows Agendia's MammaPrint Safely Reduces Chemo Use in Low-Risk Patients [Last Updated On: August 17th, 2024] [Originally Added On: March 26th, 2012]
- Abbott Challenges 'Incorrect Assumptions' in Cost-Effectiveness Study of Xalkori PGx Testing [Last Updated On: August 17th, 2024] [Originally Added On: March 26th, 2012]
- Genoptix Says NGS Melanoma Test Will Not Be Used to Place Patients in Trials for Parent Novartis [Last Updated On: August 17th, 2024] [Originally Added On: March 28th, 2012]
- St. Jude's Evans Receives Pharmacists Assn. Award [Last Updated On: August 17th, 2024] [Originally Added On: March 29th, 2012]
- Perkins Chain Hires New CEO [Last Updated On: August 17th, 2024] [Originally Added On: March 29th, 2012]
- PGx Highlights from American College of Cardiology Annual Meeting [Last Updated On: August 17th, 2024] [Originally Added On: March 29th, 2012]
- Collecting Cancer Data [Last Updated On: August 17th, 2024] [Originally Added On: March 29th, 2012]
- Study: Higher Plavix Dose Doesn't Improve Response for CYP2C19*2 Carriers; Effient May Be Best Option [Last Updated On: August 17th, 2024] [Originally Added On: March 29th, 2012]
- UNC Analysis Finds Beta1-AR Alleles Impact Survival in Patients Treated with Beta-Blockers [Last Updated On: August 17th, 2024] [Originally Added On: March 29th, 2012]
- Q&A: GE Healthcare's Mark Dente on the Challenges of Integrating Genomics Data with EMRs [Last Updated On: August 17th, 2024] [Originally Added On: March 31st, 2012]
- Eastday-Neurosurgeon, geneticist take top prizes in science [Last Updated On: August 17th, 2024] [Originally Added On: March 31st, 2012]
- A New 'Omics Emerges [Last Updated On: August 17th, 2024] [Originally Added On: April 2nd, 2012]
- Up to the Task [Last Updated On: August 17th, 2024] [Originally Added On: April 2nd, 2012]
- NHGRI Plans to Fund More Clinical Sequencing Projects [Last Updated On: August 17th, 2024] [Originally Added On: April 7th, 2012]
- Doctor’s role is key to cancer fight [Last Updated On: August 17th, 2024] [Originally Added On: April 16th, 2012]
- People in the News: Josh LaBaer in as New President of US HUPO and More [Last Updated On: August 17th, 2024] [Originally Added On: April 22nd, 2012]
- Convey, CLC Bio to Provide Combined Software, Hardware NGS Data-Analysis Solution [Last Updated On: August 17th, 2024] [Originally Added On: April 22nd, 2012]